


CLAIMS

What is claimed is:

1. A compound of Formula I, and pharmaceutically acceptable salts thereof,



Formula I

- wherein:

R_1 is $-(CR^aR^b)_n-X$;

- R^a , R^b are each independently selected from the group consisting of H, C_{1-6} alkyl; each of said C_{1-6} alkyl being optionally substituted with one to six same or different halogen;

- X is H or C_{1-6} alkyl; said C_{1-6} alkyl being optionally substituted with a member selected from the group consisting of (1) one to six same or different halogen or hydroxy, (2) heteroaryl, (3) non-aromatic heterocyclic ring and (4) a member selected from Group A;

n is 1-6;

- Group A is a member selected from the group consisting of halogen, CN, OR^x , $N^+R^cR^dR^e[T]$, NR^cR^d , COR^c , CO_2R^x , $CONR^xR^y$ and $S(O)_mR^c$; R^x and R^y are independently H or C_{1-6} alkyl; R^c , R^d and R^e are independently C_{1-6} alkyl;

m is 0-2


T⁻ is halogen, CF₃SO₃⁻ or CH₃SO₃⁻;


5 R₂ and R₅ are independently halogen or H;

R₃ and R₄ are each independently selected from the group consisting of H, halogen and C₁₋₆ alkyl; said C₁₋₆ alkyl can be optionally substituted with one to six same or different halogen;

10

Q is a member selected from the group consisting of





F_1 is CH or N;

- 5 R_6 is selected from the group consisting of H, halogen, NR^fR^g , SR^n and a five-membered heteroaryl containing one to two of the same or different heteroatoms selected from the group consisting of O, S and N;

- 10 R^f and R^g are independently H, C_{1-6} alkyl or C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with OR^h or CO_2R^h ;

R^h and R^i are independently H or C_{1-6} alkyl;

R^n is C_{1-6} alkyl optionally substituted with CO_2R^h ;

15

R_7 is H, or CO_2R^h ;

R_8 is H, COR^h , CO_2R^h or C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with OR^h ;

20

R_9 is H, halogen, heteroaryl, phenyl, phenyl substituted with a halogen group, phenyl substituted with a methanesulfonyl group, COR^h , CO_2R^h , C_{1-6} alkyl,

C₂₋₆ alkenyl, and C₂₋₄ alkynyl; said C₂₋₄ alkynyl optionally substituted with C₁₋₆ cycloalkyl;

R₁₀ and R₁₁ are independently H, NO₂ or NR^hRⁱ

5

R₁₂ is H, CO₂R^h or C₁₋₂ alkyl; said C₁₋₂ alkyl optionally substituted with phenyl;

R₁₃ and R₁₄ are independently selected from the group consisting of H, OR^h, CONR^jR^k, NR^lR^m and pyrrolidine; wherein said pyrrolidine is attached at the nitrogen atom;

10

R^j and R^k are independently H or C₁₋₆ alkyl optionally substituted with phenyl;

R^l and R^m are independently C₁₋₆ alkyl;

15

R₁₅ and R₁₆ are independently selected from the group consisting of H, OR^h, phenyl, pyridyl and C₁₋₆ alkyl; said C₁₋₆ alkyl optionally substituted with CO₂R^h;

R₁₇ and R₁₈ are independently selected from the group consisting of halogen, NR^lR^m, SR^h and morpholine; wherein said morpholine is attached at the nitrogen atom;

20

R₁₉ is selected from the group consisting of H, phenyl, C₂₋₆ alkenyl and C₁₋₆ alkyl; said C₁₋₆ alkyl optionally substituted with one to six same or different halogen, CO₂R^h, CONR^hRⁱ, pyridyl and one to three phenyl groups; wherein in the case of C₁₋₆ alkyl substituted with one phenyl group, said phenyl group is optionally substituted with a member selected from the group consisting of halogen, PO(OR^h)₂, CO₂R^h, SO₂Rⁿ and CONR^hRⁱ;

25

Rⁿ is C₁₋₆ alkyl;

30

R₂₀ and R₂₁ are independently H or halogen;

R₂₂ is C₁₋₆ alkyl;

R₂₃ and R₂₄ are independently H or C₁₋₆ alkyl;

5

R₂₅ is C₁₋₆ cycloalkyl or C₁₋₆ alkyl; said C₁₋₆ alkyl group optionally substituted with a member selected from the group consisting of CO₂R^h, PhCO₂R^h and one to six same or different halogens;

10 R₂₆ is selected from the group consisting of H, halogen, C₁₋₆ alkyl; C₂₋₆ alkenyl, OR^h and COR^h; said C₂₋₆ alkenyl being optionally substituted with OR^h;

R₂₇ is H, OR^h or CO₂R^h;

15 R₂₈ is CO₂R^h;

R₂₉ is H or halogen;

heteroaryl is a 5- or 6-membered aromatic ring containing at least one and up to
20 four non-carbon atoms selected from the group consisting of O, N and S;


non-aromatic heterocyclic ring is a 3 to 7-membered non-aromatic ring
containing at least one and up to four non-carbon atoms selected from the group
consisting of O, N and S; and

25

p is 0-2.

2. A compound of claim 1 wherein heteroaryl is selected from the group
consisting of pyridyl, thiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,4-
30 oxadiazol-5-one and tetrazole.

3. A compound of claim 1 wherein non-aromatic heterocyclic ring is selected from the group consisting of pyrrolidine and piperidine.
4. A compound of claim 1 wherein:
- 5 R^a and R^b are hydrogen.
5. A compound of claim 1 wherein:
- 10 R_1 is $-(CH_2)_n-X$ and n is 2-4.
6. A compound in claim 1 wherein R_3 and R_4 are each independently selected from the group consisting of H, fluorine and C_{1-2} alkyl; said C_{1-2} alkyl being optionally substituted with one to three fluorine atoms.
- 15 7. A compound in claim 1 wherein:
- R_1 is 3-methyl-2-butyl or $-(CH_2)_n-X$; wherein n is 2-4;
- 20 X is a member selected from the group consisting of
 $-F$, $-CN$, $-SR^c$, $-SO_2R^c$, $-OR^x$, $-COR^c$, CO_2R^x , $CONR^xR^y$,
 $[NR^cR^dR^e][T]$,



R^c , R^d and R^e are independently C_{1-4} alkyl; and

R^x and R^y are independently H or C_{1-4} alkyl.

8. A compound of claim 1 wherein:

5

R_2 and R_5 are independently H.

9. A method for treating mammals infected with RSV, and in need thereof,
which comprises administering to said mammal a therapeutically effective
10 amount of one or more of the aforementioned compounds as claimed in any one
of claims 1-8.

10. A pharmaceutical composition which comprises a therapeutically
effective amount of one or more of the aforementioned compounds as claimed in
15 any one of claims 1-8, and a pharmaceutically acceptable carrier.